摘要
急性髓系白血病(AML)是一种起源于造血干祖细胞的恶性克隆增殖性血液系统肿瘤。传统化疗可使大部分患者获得完全缓解,但截至目前,仅有异基因造血干细胞移植(allo-HSCT)是可能治愈AML的唯一方式。复发、耐药及移植相关死亡仍然是AML治疗面临的关键问题。因此,寻找新的治疗方式以改善和提高AML患者的预后在当下显得迫切需要。近年来,新型免疫治疗的出现彻底改变了过去数十年对肿瘤治疗的观念。以嵌合抗原受体T细胞(CAR-T)为代表的细胞免疫治疗和PD-1单克隆抗体为代表的免疫检测点抑制剂在血液系统恶性肿瘤中取得显著的疗效。本文就近几年CAR-T和PD-1单克隆抗体在AML临床治疗中的最新研究进展作一综述。
Acute myeloid leukemia(AML)is a malignant clonal proliferative hematological tumor that originates from hematopoietic stem progenitor cells.Traditional chemotherapy can achieve complete remission in most patients,but so far,only allogeneic hematopoietic stem cell transplantation(allo-HSCT)is the only way to cure AML.Recurrence,drug resistance,and transplant-related deaths remain a key issue for AML treatment.Therefore,finding new treatments to improve the prognosis of patients with AML is urgently needed.In recent years,the emergence of new immunotherapy has revolutionized the concept of cancer treatment in the past few decades.Cellular immunotherapy represented by chimeric-antigen receptor T cell(CAR-T)and immunological detection point inhibitor represented by PD-1 blockade have achieved remarkable effects in hematological malignancies.This article mainly reviews the recent research progress of CAR-T and PD-1 blockade in the clinical treatment of AML.
作者
王季石
WANG Ji-Shi(Department of Hematology,The Affiliated Hospital of Guizhou Medical University,Guiyang 550001,Guizhou Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2020年第3期1069-1074,共6页
Journal of Experimental Hematology
基金
国家自然科学基金(81470006)。
作者简介
通信作者:王季石,主任医师,教授,博士研究生导师.E-mail:wangjishi9646@163.com。
